Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean renzulli d[au] (1 results)?
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
Lorusso D, Raspagliesi F, Ronzulli D, Valabrega G, Colombo N, Pisano C, Cassani C, Tognon G, Tamberi S, Mangili G, Mammoliti S, De Giorgi U, Greco F, Mosconi AM, Breda E, Artioli G, Andreetta C, Casanova C, Ceccherini R, Frassoldati A, Salutari V, Giolitto S, Scambia G. Lorusso D, et al. Among authors: ronzulli d. J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225. Online ahead of print. J Clin Oncol. 2024. PMID: 38315944
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Lorusso D, Pignata S, Tamberi S, Mangili G, Bologna A, Nicoloso MS, Giolitto S, Salutari V, Mantero M, Pisano C, Bergamini A, Musacchio L, Ronzulli D, Raspagliesi F, Scambia G. Lorusso D, et al. Among authors: ronzulli d. Gynecol Oncol. 2022 Dec;167(3):436-443. doi: 10.1016/j.ygyno.2022.09.023. Epub 2022 Oct 8. Gynecol Oncol. 2022. PMID: 36220670 Clinical Trial.
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Lorusso D, et al. Among authors: ronzulli d. Target Oncol. 2021 Jan;16(1):59-68. doi: 10.1007/s11523-020-00780-4. Epub 2020 Dec 28. Target Oncol. 2021. PMID: 33369704 Free PMC article. Clinical Trial.
A decision support system based on radiomics and machine learning to predict the risk of malignancy of ovarian masses from transvaginal ultrasonography and serum CA-125.
Chiappa V, Interlenghi M, Bogani G, Salvatore C, Bertolina F, Sarpietro G, Signorelli M, Ronzulli D, Castiglioni I, Raspagliesi F. Chiappa V, et al. Among authors: ronzulli d. Eur Radiol Exp. 2021 Jul 26;5(1):28. doi: 10.1186/s41747-021-00226-0. Eur Radiol Exp. 2021. PMID: 34308487 Free PMC article.